Second CGRP antagonist, fremanezumab, listed on PBS for migraine

The anti-CGRP fremanezumab (Ajovy) has finally been listed on the PBS, but the tight criteria for subsidy may deny access for many chronic migraine patients, according to some advocates. From 1 August, neurologist-treated patients averaging 15 or more headache days per month, with at least eight days of migraine, can access fremanezumab via the PBS, ...

Already a member?

Login to keep reading.

© 2021 the limbic